Valuation: Moderna, Inc.

Market Cap 57.94B 49.63B 46.44B 42.51B 79.78B 5,544B 80.83B 549B 214B 2,785B 218B 213B 9,211B P/E 2026 *
-16.9x
P/E 2027 * -29.8x
Enterprise Value 54.29B 46.51B 43.52B 39.83B 74.76B 5,195B 75.74B 514B 200B 2,609B 204B 199B 8,631B EV / Sales 2026 *
25.8x
EV / Sales 2027 * 22.7x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day+0.58%
1 week+129.20%
Current month+164.74%
1 month+154.52%
3 months+209.58%
6 months+188.59%
Current year+392.13%
1 week 62.13
Extreme 62.1293
176.66
1 month 52.66
Extreme 52.6601
176.66
Current year 29.81
Extreme 29.81
176.66
1 year 22.28
Extreme 22.28
176.66
3 years 22.28
Extreme 22.28
176.66
5 years 22.28
Extreme 22.28
464.85
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
6/8/26 Fiscal year

Chief Executive Officer

504,938 0.1273%
15/7/26 Fiscal year

Chairperson

160,008 0.0403%
8/7/26 Free

Director

14,766 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
+8.86%+129.20%+435.14%+25.70% 57.94B
+0.90%+3.80%+41.49%-0.81% 83.28B
+0.48%+25.64%-21.85%-35.91% 57.77B
-1.46%+0.19%-2.06%+32.21% 51.75B
-0.05%+2.92%+10.30%+172.09% 49.35B
+1.13%+3.31%+55.61%-18.13% 32.03B
+0.46%+6.37%+50.29%+97.70% 25.91B
-2.83%+4.35%-0.45%+187.16% 22.74B
-1.26%-0.83%+56.44%+108.83% 16.87B
-5.74%+1.91%-1.42%+796.55% 16.08B
Average -0.77%+18.61%+62.35%+136.54% 41.37B
Weighted average by Cap. -0.16%+24.08%+76.89%+73.37%

Financials

2026 *2027 *
Net sales 2.11B 1.8B 1.69B 1.55B 2.9B 202B 2.94B 19.95B 7.78B 101B 7.91B 7.74B 335B 2.46B 2.1B 1.97B 1.8B 3.38B 235B 3.43B 23.27B 9.07B 118B 9.23B 9.03B 391B
Net income -3.38B -2.89B -2.71B -2.48B -4.65B -323B -4.71B -32B -12.48B -162B -12.69B -12.41B -537B -1.9B -1.62B -1.52B -1.39B -2.61B -181B -2.64B -17.95B -7B -91.1B -7.12B -6.96B -301B
Net Debt -3.65B -3.13B -2.92B -2.68B -5.02B -349B -5.09B -34.55B -13.48B -175B -13.7B -13.4B -580B -2.19B -1.88B -1.76B -1.61B -3.02B -210B -3.06B -20.77B -8.1B -105B -8.24B -8.06B -349B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
21/08/26 USD 145.13 +8.86% 87,316,065
20/08/26 USD 133.32 -23.55% 99,499,941
19/08/26 USD 174.38 +176.97% 199,252,328
18/08/26 USD 62.96 -2.33% 4,304,996
17/08/26 USD 64.46 +1.80% 3,979,550
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
145.13USD
Average target price
91.39USD
Spread / Average Target
-37.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock